Lv11
30 积分 2024-04-28 加入
Discovery of Highly Selective Inhibitors of Microtubule-Associated Serine/Threonine Kinase-like (MASTL)
7小时前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
12天前
已完结
The New Frontier: Merging Molecular Glue Degrader and Antibody–Drug Conjugate Modalities To Overcome Strategic Challenges
1个月前
已完结
Degrader–Antibody Conjugates: Emerging New Modality
1个月前
已完结
Degrader-antibody conjugates
1个月前
已完结
Improving Tumor Penetration of Antibodies and Antibody–Drug Conjugates: Taking Away the Barriers for Trojan Horses
1个月前
已完结
Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross-sectional study
4个月前
已完结
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
5个月前
已完结
Intravenous administration of blood–brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system
5个月前
已完结
Trispecific antibodies offer a third way forward for anticancer immunotherapy
5个月前
已完结
超声引导下经皮心肌内室间隔射频消融术治疗梗阻性肥厚型心肌病对Lown分级的影响
ORM-6151: A First-in-Class, Anti-CD33 Antibody-Enabled GSPT1 Degrader for AML
皖公网安备34019202002308
